Compare SIEB & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SIEB | KPTI |
|---|---|---|
| Founded | 1886 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.6M | 94.6M |
| IPO Year | N/A | 2013 |
| Metric | SIEB | KPTI |
|---|---|---|
| Price | $3.79 | $6.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $22.17 |
| AVG Volume (30 Days) | 23.4K | ★ 165.8K |
| Earning Date | 11-12-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | $90,289,000.00 | ★ $142,530,000.00 |
| Revenue This Year | N/A | $3.82 |
| Revenue Next Year | N/A | $3.18 |
| P/E Ratio | $21.39 | ★ N/A |
| Revenue Growth | ★ 8.32 | N/A |
| 52 Week Low | $2.08 | $3.51 |
| 52 Week High | $5.77 | $12.45 |
| Indicator | SIEB | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 72.02 | 66.79 |
| Support Level | $2.82 | $5.70 |
| Resistance Level | $3.05 | $6.05 |
| Average True Range (ATR) | 0.26 | 0.45 |
| MACD | 0.09 | 0.16 |
| Stochastic Oscillator | 90.57 | 75.69 |
Siebert Financial Corp is a diversified financial services firm and provides a full range of brokerage and financial advisory services including securities brokerage, investment advisory and insurance offerings, and corporate stock plan administration solutions. The firm mainly provides online and traditional brokerage and related services to retail investors and also acts as an investment advisor for its subsidiary. The company operates in the securities brokerage and asset management industry. It also engages in Insurance services, Robo-advisory technology, and Prime brokerage business through its subsidiaries.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.